Digital healthcare firm iRhythm beats Q1 revenue expectations

iRhythm Holdings

30/04/2026 21:34

Overview

Digital cardiac monitoring firm's Q1 revenue rose 25.7% yr/yr, beating analyst expectations

Adjusted net loss narrowed yr/yr, driven by revenue growth and operating leverage

Outlook

iRhythm sees 2026 revenue between $875 mln and $885 mln

Company expects 2026 adjusted EBITDA margin of 12% to 13%

Result Drivers

VOLUME-LED GROWTH - Revenue increase was primarily driven by sustained volume demand across the customer base, reflecting strength in core business and newer growth channels

OPERATIONAL EFFICIENCIES - Gross margin expansion was mainly due to operational efficiencies and scale benefits from higher volumes

CHANNEL DIVERSIFICATION - Company saw meaningful contributions from Zio monitor, Zio AT, innovative partnerships, and international markets

Company press release: ID:nGNX80DBk7

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$199.4 mln
$194.03 mln (15 Analysts)
Q1 Adjusted Net Income
-$11.3 mln
Q1 Net Income
-$13.90 mln
Q1 Gross Margin
70.90%
Q1 Gross Profit
$141.4 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for iRhythm Holdings, Inc is $200.00, about 65.6% above its April 29 closing price of $120.75

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)